Drug company executives to testify before Senate

  • 📰 ChannelNewsAsia
  • ⏱ Reading Time:
  • 42 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 20%
  • Publisher: 66%

United Kingdom News News

United Kingdom United Kingdom Latest News,United Kingdom United Kingdom Headlines

Seven drug company executives will testify about rising prescription drug prices before a powerful U.S. Senate Committee on Tuesday, marking a ...

WASHINGTON/NEW YORK: Seven drug company executives will testify about rising prescription drug prices before a powerful U.S. Senate Committee on Tuesday, marking a sharp escalation in lawmakers' promises to address high medicine costs.

U.S. President Donald Trump has said drugmakers are"getting away with murder," and his administration has made bringing down prescription medicine prices a top priority. The U.S. Department of Health and Human Services last year rolled out a plan to lower drug prices and has introduced several modest proposals to curb medicine costs, but Democrats have said Trump and his administration are not doing enough.

Pharmaceutical companies have blamed high research and development costs for their prices and after-market discounts called rebates that they must provide to pharmacy benefits managers in order to gain patient access to their products by having them included on preferred coverage lists. HHS has proposed a rule to eliminate rebates in Medicare and Medicaid, the government health insurance programs.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 6. in UK
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

United Kingdom United Kingdom Latest News, United Kingdom United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Pharma stocks could see turbulence from US Senate drug-price hearingU.S. healthcare stocks could face more turbulence on Tuesday, after a bumpy early 2019, as top executives from some of the largest pharmaceutical ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »